This site is intended for health professionals only

GSK unveils plans for neurology drugs


GlaxoSmithKline (GSK) has presented an overview of its neuroscience portfolio and the company’s disease strategy to investors and analysts at a meeting in New York.

The portfolio spans 13 different areas, including Alzheimer’s disease, depression, schizophrenia and multiple sclerosis.

The company revealed that:

  • More than 25 innovative compounds are in development, with 15 new mechanisms of action.
  • Eight approvals, eight filings and nine key assets have started phase III trials so far in 2007.
  • FDA filing of Promacta, a new oral treatment for short-term idiopathic thrombocytopenic purpura, will be submitted shortly.

Moncef Slaoui, GSK’s chairman of research and development (R&D), said: “GSK continues to make good progress with its pipeline and we have set out our vision in the area of neuroscience.

“Alongside vaccines, oncology and biopharmaceuticals, this is a key area for additional R&D investment and future growth for GSK.

“Diseases such as schizophrenia, Alzheimer’s and Parkinson’s disease present a chronic and ever-expanding burden to patients, caregivers and healthcare systems across the world.

“Every 72 seconds, a person is diagnosed with Alzheimer’s disease. The urgency to provide medical solutions for this and other neurological diseases has never been greater.”

Copyright © PA Business 2007


Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine